[Physiological trials with MIF-I in Parkinson's disease (author's transl)].
The writers present some physiological (and not therapeutic) acute and sub-acute trials with tripeptide: L-propyl-L-leucyl-glycine amide (M.I.F.-I) in Parkinson's Disease. This work confirms the earlier observation that M.I.F.-I employed alone or in combination with Levodopa is active against Parkinson's disease. The writers evoke the hypothesis that this action takes place at the postsynaptic receptors, whose configuration may be modified in the sense of a hypersensitivity. These studies justify undertaking a series of controlled therapeutic trials when the cost of the product permits and as well instituting development work on analogues active orally.
D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007361:Intelligence Tests; D009075:MSH Release-Inhibiting Hormone / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000097:blood; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy
D000978:Antiparkinson Agents; D009074:Melanocyte-Stimulating Hormones; D009075:MSH Release-Inhibiting Hormone
Essais physiologiques avec le M.I.F.-I dans la maladie de Parkinson.